Compugen Ltd. (CGEN) vs Protalix BioTherapeutics, Inc. (PLX)

Compugen Ltd. and Protalix BioTherapeutics, Inc. are both Biotechnology companies. Compugen Ltd. and Protalix BioTherapeutics, Inc. are of similar size ($224.5M and $221.6M). Compugen Ltd. trades at the lower P/E: 6.3× against 11.3×. Compugen Ltd. grew revenue faster over the last twelve months: 234.2% against 30.1%. Compugen Ltd. has the higher net margin (47.6% vs 23.5%) and the lower return on invested capital (0.00% vs 48.5%). Across the 20 metrics below, Compugen Ltd. leads on 18 and Protalix BioTherapeutics, Inc. on 2.

Valuation

Metric CGEN PLX Biotechnology median
P/E 6.26 11.33 7.88
P/S 3.04 2.70 11.47
P/B 2.54 3.05 2.52
Price to free cash flow 5.63 28.37 21.16
EV/EBITDA 3.30 7.27 0.74
EV/Sales 1.35 2.24 10.73
Earnings yield 15.97% 8.82% (28.84%)
Free cash flow yield 17.78% 3.52% (23.03%)

Profitability

Metric CGEN PLX Biotechnology median
Gross margin 86.89% 69.20% 65.16%
Operating margin 40.94% 28.89% 0.00%
Net margin 47.55% 23.50% 0.00%
Free cash flow margin 54.10% 9.51% 0.00%
Return on equity 47.85% 31.23% (57.72%)
Return on assets 23.86% 20.07% (49.22%)
Return on invested capital 0.00% 48.48% 0.00%

Growth

Metric CGEN PLX Biotechnology median
Revenue growth (TTM) 234.18% 30.14% 5.64%
EPS growth (last fiscal year) 337.50% (300.00%) —
Revenue growth, 5-year CAGR 105.20% (3.46%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CGEN PLX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.72 2.94 4.73
Net debt to EBITDA (4.65) 7.68 0.96

Dividend

Metric CGEN PLX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CGEN PLX Biotechnology median
Market cap 224.51m 221.57m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack